Get to know our clinical trials
Trial of elranatamab in participants with newly diagnosed multiple myeloma ineligible for transplantation.
THE GOAL OF PART 1 IS TO FIND THE BEST DOSE OF ELRANATAMAB (ALSO KNOWN AS PF-06863135) AND LENALIDOMIDE WHEN GIVEN IN COMBINATION WITH ANOTHER DRUG CALLED DARATUMUMAB FOR USE IN PART 2 AND TO LEARN ABOUT THE SAFETY AND EFFECTS OF THIS COMBINATION ON THE BODY. ELRANATAMAB, DARATUMUMAB AND LENALIDOMIDE ARE STUDY DRUGS THAT ARE NOT APPROVED FOR USE IN COMBINATION.
Technical Summary
- PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED, TWO-ARM, TWO-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) DARATUMUMAB LENALIDOMIDE COMPARED WITH DARATUMUMAB LENALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR TRANSPLANTATION. IMMUNOTHERAPY
- Code EudraCT: 2021-000803-20
- Protocol number: C1071006
- Promoter: Pfizer
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.